MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025

SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clinical microbiology, infectious diseases, and infection control, ESCMID Global serves as a pivotal platform for scientific exchange. Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", Stock Code: 688373) will present 15 new clinical and preclinical research datasets related to its pipeline products in poster presentations during the conference. The presentations will focus on two core products: Contezolid and MRX-5.

MRX-5: Preclinical and Phase 1 data supporting its potential as a novel treatment for nontuberculous mycobacterial (NTM) pulmonary disease, particularly Mycobacterium abscessus (MAB) infections.

                                         
            Title       Category          Time        Location



            Pharmacokinetic/Pharmacodynamic                Oral poster      April 12,      Arena 3
    Evaluation of MRX-5 in Murine Models of             presentation     8:30-9:30
    Mycobacterium abscessus Pulmonary                                        am
    Disease



            Benzoxaborole Antimycobacterial MRX-            Top-rated       April 13,       poster
    5: Preclinical Pharmacokinetics and in                 poster       12:00-13:30    area, Hall
                                                                                            D
    vitro Drug-Drug Interaction                                              pm



            13-week Repeat-Dose Toxicology                    Poster        April 13,       poster
    Studies of MRX-5 in Sprague Dawley Rats                             12:00-13:30
    and Beagle Dogs                                                          pm            area, Hall
                                                                                                D



            Safety, tolerability and pharmacokinetics         Poster        April 13,       poster
    of single and multiple ascending doses                              12:00-13:30    area, Hall
                                                                                            D
    and food-effect of MRX-5 tablets in                                      pm
    healthy adult subjects

Four studies on MRX-5 presented at the conference

"We are excited to share our latest clinical and scientific advancements at ESCMID Global 2025," Dr. Zhengyu Yuan, Chairman and CEO of MicuRx, stated?"These data highlighted our ongoing commitment to developing innovative therapies to address urgent unmet needs in infectious and chronic pulmonary diseases."

MicuRx invites attendees to visit the poster sessions to engage with the team and learn more about the company's clinical progress and future development plans.

View original content:https://www.prnewswire.com/news-releases/micurx-15-clinical-and-preclinical-research-studies-to-be-presented-at-escmid-global-2025-302423147.html

SOURCE MicuRx Pharmaceuticals